XML 98 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration and license agreements (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2024 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:  
Research and development targets$16,688 $15,200 
Option rights2,376 2,376 
Total$19,064 $17,576 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three months ended March 31, 2024 and 2023 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended March 31,
 20242023
Revenue from collaboration agreements:  
MKDG Agreement$55 $— 
Merck Agreement645 — 
Roche Agreement1,488 353 
Biogen Agreement851 2,336 
Calico Agreement— 1,070 
Total revenue from collaboration agreements$3,039 $3,759 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of March 31, 2024 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
MKDG Agreement$13,523 $5,832 $10,168 $16,000 
Merck Agreement— 9,355 9,355 
Betta Agreements— 17,000 — 17,000 
Roche Agreement— 2,955 10,538 13,493 
Biogen Agreement76 — — — 
Total$13,599 $35,142 $20,706 $55,848 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2023 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Merck Agreement$10,000 $8,000 $2,000 $10,000 
Betta Agreement1,799 4,000 8,000 12,000 
Roche Agreement— 2,667 11,814 13,493 
Biogen Agreement— 804 — 804 
Total$11,799 $15,471 $21,814 $37,285 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three months ended March 31, 2024 and 2023 are (in thousands):
Three Months Ended March 31,
20242023
Revenue recognized that was included in the contract liability at the beginning of the period$2,744 $3,231